BAY 11-7082 induces cell death through NF-κB-independent mechanisms in the Ewing's sarcoma family of tumours

Cancer Letters

Volumn 268, Issue 2, 2008, Pages 212-224

  White, Danielle E ^a   Burchill, Susan A ^a  

^a IMPERIAL CANCER RESEARCH FUND   (United Kingdom)

Author keywords

BAY 11 7082; Cell death; Ewing's sarcoma family of tumours; Fenretinide; NF B; TNF

Indexed keywords

3 (4 METHYLPHENYLSULFONYL) 2 PROPENENITRILE; CASPASE 3; FENRETINIDE; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; MITOGEN ACTIVATED PROTEIN KINASE P38; REACTIVE OXYGEN METABOLITE; TUMOR NECROSIS FACTOR ALPHA;

ARTICLE; CANCER CELL DESTRUCTION; CANCER FAMILY; CELL DEATH; CELL SURVIVAL; CELL VIABILITY; CONTROLLED STUDY; DRUG EFFECT; DRUG POTENTIATION; ENZYME DEGRADATION; EWING SARCOMA; HUMAN; HUMAN CELL; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN PHOSPHORYLATION;

APOPTOSIS; BONE NEOPLASMS; CELL LINE, TUMOR; FENRETINIDE; HUMANS; I-KAPPA B PROTEINS; NF-KAPPA B; NITRILES; P38 MITOGEN-ACTIVATED PROTEIN KINASES; PHOSPHORYLATION; REACTIVE OXYGEN SPECIES; SARCOMA, EWING'S; SULFONES; TRANSCRIPTION FACTOR RELA; TUMOR NECROSIS FACTOR-ALPHA;

EID: 48549090173     PISSN: 03043835     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.canlet.2008.03.045     Document Type: Article

References (44)

1. Ulukaya E., and Wood E.J. Fenretinide and its relation to cancer. Cancer Treat. Rev. 25 (1999) 229-235
2. Camerini T., Mariani L., De Palo G., Marubini E., Di Mauro M.G., Decensi A., Costa A., and Veronesi U. Safety of the synthetic retinoid fenretinide: long-term results from a controlled clinical trial for the prevention of contralateral breast cancer. J. Clin. Oncol. 19 (2001) 1664-1670
3. Garaventa A., Luksch R., Lo Piccolo M.S., Cavadini E., Montaldo P.G., Pizzitola M.R., Boni L., Ponzoni M., Decensi A., De Bernardi B., Bellani F.F., and Formelli F. Phase I trial and pharmacokinetics of fenretinide in children with neuroblastoma. Clin. Cancer Res. 9 (2003) 2032-2039
4. Villablanca J.G., Krailo M.D., Ames M.M., Reid J.M., Reaman G.H., and Reynolds C.P. Phase I trial of oral fenretinide in children with high-risk solid tumors: a report from the Children's Oncology Group (CCG 09709). J. Clin. Oncol. 24 (2006) 3423-3430
5. MAPK-dependent sensitivity of Ewing's sarcoma family of tumors to fenretinide-induced cell death. Clin. Cancer Res. 11 (2005) 3136-3148
6. Dmitrovsky E. Fenretinide activates a distinct apoptotic pathway. J. Natl. Cancer Inst. 96 (2004) 1264-1265
7. Hail N., Kim H.J., and Lotan R. Mechanisms of fenretinide-induced apoptosis. Apoptosis 11 (2006) 1677-1694
8. Goranov B.B., Campbell Hewson Q.D., Pearson A.D., and Redfern C.P. Overexpression of RARgamma increases death of SH-SY5Y neuroblastoma cells in response to retinoic acid but not fenretinide. Cell Death Differ. 13 (2006) 676-679
9. Sheikh M.S., Shao Z.M., Li X.S., Ordonez J.V., Conley B.A., Wu S., Dawson M.I., Han Q.X., Chao W.R., Quick T., Niles R.M., and Fontana J.A. N-(4-hydroxyphenyl)retinamide (4-HPR)-mediated biological actions involve retinoid receptor-independent pathways in human breast carcinoma. Carcinogenesis 16 (1995) 2477-2486
10. Formelli F., Barua A.B., and Olson J.A. Bioactivities of N-(4-hydroxyphenyl) retinamide and retinoyl beta-glucuronide. FASEB J. 10 (1996) 1014-1024
11. Boya P., Morales M.C., Gonzalez-Polo R.A., Andreau K., Gourdier I., Perfettini J.L., Larochette N., Deniaud A., Baran-Marszak F., Fagard R., Feuillard J., and Asumendi A. The chemopreventive agent N-(4-hydroxyphenyl)retinamide induces apoptosis through a mitochondrial pathway regulated by proteins from the Bcl-2 family. Oncogene 22 (2003) 6220-6230
12. Simeone A.M., Li Y.J., Broemeling L.D., Johnson M.M., Tuna M., and Tari A.M. Cyclooxygenase-2 is essential for HER2/neu to suppress N-(4-hydroxyphenyl)retinamide apoptotic effects in breast cancer cells. Cancer Res. 64 (2004) 1224-1228
13. Hewson Q.D., Lovat P.E., Corazzari M., Catterall J.B., and Redfern C.P. The NF-kappaB pathway mediates fenretinide-induced apoptosis in SH-SY5Y neuroblastoma cells. Apoptosis 10 (2005) 493-498
14. Hayden M.S., and Ghosh S. Signalling to NF-κB. Genes Dev. 18 (2004) 2195-2224
15. Perkins N.D. Integrating cell-signalling pathways with NF-κB and IKK function. Nat. Rev. Mol. Cell Biol. 8 (2007) 49-62
16. Luo J.L., Kamata H., and Karin M. IKK/NF-κB signalling: balancing life and death-a new approach to cancer therapy. J. Clin. Invest. 115 (2005) 2625-2632
17. Dutta J., Fan Y., Gupta N., Fan G., and Gélinas C. Current insights into the regulation of programmed cell death by NF-κB. Oncogene 25 (2006) 6800-6816
18. Radhakrishnan S.K., and Kamalakaran S. Pro-apoptotic role of NF-κB: implications for cancer therapy. Biochim. Biophys. Acta 1766 (2006) 53-62
19. Perkins N.D., and Gilmore N.D. Good cop bad cop: the different faces of NF-κB. Cell Death Differ. 13 (2006) 769-772
20. May M.J., and Ghosh S. IκB kinases: Kinsmen with different crafts. Science 284 (1999) 271-273
21. Nakanishi C., and Toi M. Nuclear factor-kappaB inhibitors as sensitizers to anticancer drugs. Nat. Rev. Cancer 5 (2005) 297-309
22. Rayet B., and Gelinas C. Aberrant rel/nfκb genes and activity in human cancer. Oncogene 18 (1999) 6938-6947
23. Javelaud D., and Besancon F. NF-kappa B activation results in rapid inactivation of JNK in TNF alpha-treated Ewing sarcoma cells: a mechanism for the anti-apoptotic effect of NF-kappa B. Oncogene 20 (2001) 4365-4372
24. Djavaheri-Mergny M., Javelaud D., Wietzerbin J., and Besancon F. NF-kappaB activation prevents apoptotic oxidative stress via an increase of both thioredoxin and MnSOD levels in TNFalpha-treated Ewing sarcoma cells. FEBS Lett. 578 (2004) 111-115
25. Javelaud D., Poupon M.F., Wietzerbin J., and Besancon F. Inhibition of constitutive NF-kappa B activity suppresses tumorigenicity of Ewing sarcoma EW7 cells. Int. J. Cancer 98 (2002) 193-198
26. Pierce J.W., Schoenleber R., Jesmok G., Best J., Moore S.A., Collins T., and Gerritsen M.E. Novel inhibitors of cytokine-induced IkappaBalpha phosphorylation and endothelial cell adhesion molecule expression show anti-inflammatory effects in vivo. J. Biol. Chem. 272 (1997) 21096-21103
27. Dauphinot L., De Oliveira C., Melot T., Sevenet N., Thomas V., Weissman B.E., and Delattre O. Analysis of the expression of cell cycle regulators in Ewing cell lines: EWS-FLI-1 modulates p57KIP2 and c-Myc expression. Oncogene 20 (2001) 3258-3265
28. NTR. J. Biol. Chem. 279 (2004) 47912-47928
29. Enari M., Sakahira H., Yokoyama H., Okawa K., Iwamatsu A., and Nagata S. A caspase-activated DNase that degrades DNA during apoptosis, and its inhibitor ICAD. Nature 391 (1998) 43-50
30. Kivinen K., Kallajoki M., and Taimen P. Caspase-3 is required in the apoptotic disintegration of the nuclear matrix. Exp. Cell Res. 311 (2005) 62-73
31. Dai Y., Rahmani M., Dent P., and Grant S. Blockade of histone deacetylase inhibitor-induced RelA/p65 acetylation and NF-kappaB activation potentiates apoptosis in leukemia cells through a process mediated by oxidative damage, XIAP downregulation, and c-Jun N-terminal kinase 1 activation. Mol. Cell Biol. 25 (2005) 5429-5444
32. Thevenod F., Friedmann J.M., Katsen A.D., and Hauser I.A. Upregulation of multidrug resistance P-glycoprotein via nuclear factor-kappaB activation protects kidney proximal tubule cells from cadmium- and reactive oxygen species-induced apoptosis. J. Biol. Chem. 275 (2000) 1887-1896
33. Corbetta S., Vicentini L., Ferrero S., Lania A., Mantovani G., Cordella D., Beck-Peccoz P., and Spada A. Activity and function of the nuclear factor kappaB pathway in human parathyroid tumors. Endocr. Relat. Cancer 12 (2005) 929-937
34. Gao R., and Brigstock D.R. Activation of nuclear factor kappa B (NF-kappaB) by connective tissue growth factor (CCN2) is involved in sustaining the survival of primary rat hepatic stellate cells. Cell Commun. Signal 3 (2005) 14
35. Shimada K., Nakamura M., Ishida E., Kishi M., Yonehara S., and Konishi N. Contributions of mitogen-activated protein kinase and nuclear factor kappa B to N-(4-hydroxyphenyl)retinamide-induced apoptosis in prostate cancer cells. Mol. Carcinog. 35 (2002) 127-137
36. Hu X., Janssen W.E., Moscinski L.C., Bryington M., Dangsupa A., Rezai-Zadeh N., Babbin B.A., and Zuckerman K.S. An IkappaBalpha inhibitor causes leukemia cell death through a p38 MAP kinase-dependent, NF-kappaB-independent mechanism. Cancer Res. 61 (2001) 6290-6296
37. Cory A.H., and Cory J.G. Induction of apoptosis in p53-deficient L1210 cells by an I-kappa-B-alpha-inhibitor (BAY 11-7085) via a NF-kappa-B-independent mechanism. Adv. Enzyme Regul. 45 (2005) 85-93
38. Budihardjo I.I., Poirier G.G., and Kaufmann S.H. Apparent cleavage of poly(ADP-ribose) polymerase in non-apoptotic mouse LTA cells: an artifact of cross-reactive secondary antibody. Mol. Cell Biochem. 178 (1998) 245-249
39. Jones R.A., Johnson V.L., Hinton R.H., Poirier G.G., Chow S.C., and Kass G.E. Liver poly(ADP-ribose)polymerase is resistant to cleavage by caspases. Biochem. Biophys. Res. Commun. 256 (1999) 436-441
40. Abadie A., Besancon F., and Wietzerbin J. Type I interferon and TNFalpha cooperate with type II interferon for TRAIL induction and triggering of apoptosis in SK-N-MC EWING tumor cells. Oncogene 23 (2004) 4911-4920
41. Karin M., and Lin A. NF-kappaB at the crossroads of life and death. Nat. Immunol. 3 (2002) 221-227
42. Park J.H., Liu L., Kim I.H., Kim J.H., You K.R., and Kim D.G. Identification of the genes involved in enhanced fenretinide-induced apoptosis by parthenolide in human hepatoma cells. Cancer Res. 65 (2005) 2804-2814
43. French L.E., and Tschopp J. The TRAIL to selective tumor death. Nat. Med. 5 (1999) 146-147
44. Shishodia S., Gutierrez A.M., Lotan R., and Aggarwal B.B. N-(4-hydroxyphenyl)retinamide inhibits invasion, suppresses osteoclastogenesis, and potentiates apoptosis through down-regulation of I(κ)B(α) kinase and nuclear factor-κB-regulated gene products. Cancer Res. 65 (2005) 9555-9565